Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ohara Confident of Overcoming Sankyo's Patents on Mevalotin
July 14, 2003
- DIAGNOSTIC NEWS IN BRIEF
July 14, 2003
- ON THE MOVE
July 14, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 14, 2003
- Drug Industry Calls For Budget, Tax Reforms to Strengthen Its Competitiveness
July 14, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 14, 2003
- Versions of Mevalotin, Lipovas Launched by All 4 Top GE Houses
July 14, 2003
- Tsuruha: Sales Increase 14.8% to \116 Bil.
July 14, 2003
- BUSINESS NEWS IN BRIEF
July 14, 2003
- BULLETIN
July 14, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 14, 2003
- Gatiflo Makes Dainippon Revise Mid-term Plan: President Miyatake
July 14, 2003
- 415 GEs, 145 Ingredients Added to NHI Price List
July 14, 2003
- FY2003 Basic Policy on Fiscal, Structural Reform Announced
July 14, 2003
- WORLD NEWS IN BRIEF
July 14, 2003
- Regulatory Reform Council Chairman Satisfied with FY2003 Basic Policy
July 14, 2003
- Mevalotin Retains Top Position, Followed by Gaster, Blopress: Survey
July 14, 2003
- Korosho Council Listens to Industry's Views on Action Plan
July 14, 2003
- Eisai to Beef Up Business Infrastructure in China
July 14, 2003
- 6 Drugs, Recommended for Approval in July
July 14, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…